These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 33857553)
1. Recent trends in drug-delivery systems for the treatment of diabetic retinopathy and associated fibrosis. Silva M; Peng T; Zhao X; Li S; Farhan M; Zheng W Adv Drug Deliv Rev; 2021 Jun; 173():439-460. PubMed ID: 33857553 [TBL] [Abstract][Full Text] [Related]
2. Current nanotechnology approaches for the treatment and management of diabetic retinopathy. Fangueiro JF; Silva AM; Garcia ML; Souto EB Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):307-22. PubMed ID: 25536109 [TBL] [Abstract][Full Text] [Related]
3. Current treatment strategies and nanocarrier based approaches for the treatment and management of diabetic retinopathy. Selvaraj K; Gowthamarajan K; Karri VV; Barauah UK; Ravisankar V; Jojo GM J Drug Target; 2017 Jun; 25(5):386-405. PubMed ID: 28122462 [TBL] [Abstract][Full Text] [Related]
4. Recent advances in intraocular and novel drug delivery systems for the treatment of diabetic retinopathy. Sharma DS; Wadhwa S; Gulati M; Kadukkattil Ramanunny A; Awasthi A; Singh SK; Khursheed R; Corrie L; Chitranshi N; Gupta VK; Vishwas S Expert Opin Drug Deliv; 2021 May; 18(5):553-576. PubMed ID: 33143473 [No Abstract] [Full Text] [Related]
5. Current and Future Pharmacologic Therapies for Diabetic Retinopathy. Villegas VM; Schwartz SG Curr Pharm Des; 2018; 24(41):4903-4910. PubMed ID: 30706803 [TBL] [Abstract][Full Text] [Related]
6. Progress of Nanotechnology in Diabetic Retinopathy Treatment. Liu Y; Wu N Int J Nanomedicine; 2021; 16():1391-1403. PubMed ID: 33658779 [TBL] [Abstract][Full Text] [Related]
7. Basic and clinical aspects of gene therapy for retinopathy induced by diabetes. Ting JH; Martin DK Curr Gene Ther; 2006 Apr; 6(2):193-214. PubMed ID: 16611042 [TBL] [Abstract][Full Text] [Related]
8. Computational systems biology approach to identify novel pharmacological targets for diabetic retinopathy. Platania CBM; Leggio GM; Drago F; Salomone S; Bucolo C Biochem Pharmacol; 2018 Dec; 158():13-26. PubMed ID: 30222965 [TBL] [Abstract][Full Text] [Related]
9. Drug, delivery and devices for diabetic retinopathy (3Ds in DR). Nirmal J; Radhakrishnan K; Moreno M; Natarajan JV; Laude A; Lim TH; Venkatraman S; Agrawal R Expert Opin Drug Deliv; 2016 Nov; 13(11):1625-1637. PubMed ID: 27169870 [TBL] [Abstract][Full Text] [Related]
10. Diabetic retinopathy: pathogenic mechanisms and current treatments. Chistiakov DA Diabetes Metab Syndr; 2011; 5(3):165-72. PubMed ID: 22813573 [TBL] [Abstract][Full Text] [Related]
11. Prospective for Diagnosis and Treatment of Diabetic Retinopathy. Himasa FI; Singhal M; Ojha A; Kumar B Curr Pharm Des; 2022; 28(7):560-569. PubMed ID: 34781866 [TBL] [Abstract][Full Text] [Related]
12. Posterior segment drug delivery for the treatment of exudative age-related macular degeneration and diabetic macular oedema. Wong CW; Wong TT Br J Ophthalmol; 2019 Oct; 103(10):1356-1360. PubMed ID: 31040133 [TBL] [Abstract][Full Text] [Related]
13. Management of Complications and Vision Loss from Proliferative Diabetic Retinopathy. Crabtree GS; Chang JS Curr Diab Rep; 2021 Sep; 21(9):33. PubMed ID: 34477996 [TBL] [Abstract][Full Text] [Related]
17. Enhancement of scutellarin oral delivery efficacy by vitamin B12-modified amphiphilic chitosan derivatives to treat type II diabetes induced-retinopathy. Wang J; Tan J; Luo J; Huang P; Zhou W; Chen L; Long L; Zhang LM; Zhu B; Yang L; Deng DY J Nanobiotechnology; 2017 Mar; 15(1):18. PubMed ID: 28249594 [TBL] [Abstract][Full Text] [Related]
18. Early pars plana vitrectomy for proliferative diabetic retinopathy: update and review of current literature. Berrocal MH; Acaba-Berrocal L Curr Opin Ophthalmol; 2021 May; 32(3):203-208. PubMed ID: 33770016 [TBL] [Abstract][Full Text] [Related]